Sana Biotechnology (NASDAQ:SANA) Shares Up 6.8% – Should You Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA) traded up 6.8% during trading on Monday . The company traded as high as $3.47 and last traded at $3.3950. Approximately 529,515 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 3,177,092 shares. The stock had previously closed at $3.18.

Analyst Ratings Changes

Several brokerages recently commented on SANA. Rodman & Renshaw started coverage on Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 price target on the stock. Wedbush increased their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Finally, Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Sana Biotechnology Trading Up 3.6%

The stock has a market cap of $916.97 million, a price-to-earnings ratio of -3.55 and a beta of 2.13. The stock’s 50-day simple moving average is $3.26 and its 200-day simple moving average is $3.57.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, equities research analysts forecast that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current year.

Institutional Trading of Sana Biotechnology

A number of institutional investors have recently bought and sold shares of SANA. Rockefeller Capital Management L.P. boosted its position in shares of Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares in the last quarter. LRI Investments LLC purchased a new stake in shares of Sana Biotechnology during the 4th quarter valued at $41,000. Jacobi Capital Management LLC bought a new stake in Sana Biotechnology in the fourth quarter worth about $41,000. Mercer Global Advisors Inc. ADV purchased a new position in Sana Biotechnology in the third quarter valued at approximately $36,000. Finally, Cibc World Markets Corp bought a new position in shares of Sana Biotechnology during the 4th quarter worth $44,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.